Biotech IPO mar­ket looks to ramp back up as BMS part­ner Ike­na and its im­munome­tab­o­lism ther­a­pies eye pub­lic of­fer­ing

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

The IPO mar­ket has cooled off a tad from its ear­ly-year mo­men­tum, when the in­dus­try raised near­ly $3 bil­lion com­bined in Jan­u­ary and Feb­ru­ary. But an­oth­er com­pa­ny has now filed to go pub­lic, one that saw in­ter­est from the deal­mak­ers at Cel­gene be­fore its ac­qui­si­tion by Bris­tol My­ers Squibb.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER